Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
Abstract
Recently immunotherapy has made considerable progress in cancer treatment. Pembrolizumab is a humanized monoclonal antibody against immune checkpoint programmed death 1 (PD‐1) receptor that is approved for the treatment of unresectable or metastatic melanoma and lung cancer 1,2.
Source: Clinical and Experimental Ophthalmology - Category: Opthalmology Authors: Chia ‐Chieh Hsiao, Ming Yao, Jia‐Hau Liu, Wei‐Li Chen Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Chia | Immunotherapy | Lung Cancer | Lung Transplant | Melanoma | Opthalmology | Skin Cancer | Stem Cell Therapy | Stem Cells | Toxicology | Transplants